Syracuse

[Central giant cell granuloma in children: Presentation of different therapeutic options].

Archive ouverte

Pham Dang, N. | Longeac, M. | Picard, M. | Devoize, Laurent | Barthélémy, I.

Edité par CCSD ; Société Française de Stomatologie Chirurgie Maxillo-faciale et de Chirurgie Orale (SFSCMFCO) / Elsevier -

International audience. Central giant cell granuloma (CGCG) is a benign tumor that may be subdivided in a non-aggressive form and an aggressive form. In aggressive forms, tumor size and high recurrence risk need large surgical resections. In order to minimize surgical morbidity, especially in children, medical treatments acting on the tumor proliferation are currently being assessed: steroids (triamcinolone), anti-osteoclastic drugs (calcitonine, alendronate, denosumab), anti-angiogenic drugs (interferon α). However to date, there is no evidence for any superiority of medical over surgical treatment. Complete response is rarely obtained and additional surgery is often necessary to remove the tumor in case of tumor progression, to remove a remnant or to remodel bone. Moreover, these drugs have frequent local or systemic side effects such as osteonecrosis and growth deficiencies.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion